JeffreyE.GershenwaldMDFACS, FAAAS, FRACS(Hon)

Surgical Oncology (Other than Breast)

Dr. John M. Skibber Professor, Department of Surgical Oncology The University of Texas MD Anderson Cancer Center

Dr. Gershenwald is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Jeffrey Gershenwald is a general surgeon in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Weill Cornell Medicine and has been in practice 27 years. He specializes in surgical oncology (other than breast) and is experienced in surgical oncology (non-breast).

University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 1995 - 1998
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1990 - 1995
Weill Cornell MedicineClass of 1990

Honorary Fellow, Royal Australasian College of Surgeons (RACS) Royal Australasian College of Surgeons, 2021
AACR Team Science Award American Association for Cancer Research, 2020
Fellow, American Association for the Advancement of Science (AAAS) American Association for the Advancement of Science, 2018
Fellow, American College of Surgeons (FACS) American College of Surgeons, 2002
Regional Top Doctor Castle Connolly, 2014
Join now to see all

PubMed

Bills to Restrict Access to and Harm From Indoor Tanning Facilities in US State Legislatures, 1992‒2023.
David B Buller, Julia Berteletti, Carolyn Heckman, Kevin R J Schroth, Alan C Geller
American Journal of Public Health. 2024-11-21
Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report.
Saul Turcios Escobar, Richard Yang, Kelly C Nelson, Jeffrey E Gershenwald, Hussein Tawbi
Journal of Cutaneous Pathology. 2024-09-01
2 citations
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, Julie Simon, Aikaterini Dedeilia
Journal of Clinical Oncology. 2024-04-01

Journal Articles

Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
Janice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
Scott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
Richard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
Pathological Assessment of Resection Specimens After Neoadjuvant Therapy for Metastatic Melanoma
M T Tetzlaff, J E Gershenwald, X Xu, V G Prieto, T Mitchell, M A Davies, J M Taube, Annals of Oncology
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
Michael A Davies, Jeffrey E Gershenwald, Clinical Cancer Research
Join now to see all

Lectures

Malignant Melanoma Prevention: Lifestyle Changes and Legislation
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Jeffrey Gershenwald, MD, Annals of Surgical Oncology
https://www.doximity.com/articles/ce96a6ac-03c0-43cd-9b57-9a526c8d8262
UpToDate, Wolters Kluwer Health - 2013-03-21

Melanoma Survivor: Protect Your SkinMarch 19th, 2019
Stage IV Salivary Gland Cancer Survivor: How Proton Therapy Saved My CareerJanuary 9th, 2019
Guidelines of Care for the Management of Primary Cutaneous MelanomaJanuary 1st, 2019
Join now to see all

Informatics, Tissue Resource, And Pathology CoreNational Cancer Institute2010–2011
Core--Informatics, Tissue Resource, And PathologyNational Cancer Institute2007–2008
Molecular Epidemiology Of Genetic Markers In MelanomaNational Cancer Institute2004–2008
Core--Nformatics, Tissue Resource, And PathologyNational Cancer Institute2004–2006